| Identification | Back Directory | [Name]
PPTN (free base) | [CAS]
1160271-30-6 | [Synonyms]
PPTN (free base)
2-Naphthalenecarboxylic acid, 4-[4-(4-piperidinyl)phenyl]-7-[4-(trifluoromethyl)phenyl]- | [Molecular Formula]
C29H24F3NO2 | [MDL Number]
MFCD34469294 | [MOL File]
1160271-30-6.mol | [Molecular Weight]
475.5 |
| Chemical Properties | Back Directory | [Boiling point ]
598.8±50.0 °C(Predicted) | [density ]
1.259±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: 10mg/mL, clear | [form ]
powder | [pka]
4.02±0.30(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Uses]
PPTN is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity[1]. | [Biological Activity]
PPTN is a very potent (IC50 = 1 nM) P2Y14 receptor antagonist th at does not interact with any other P2Y receptor at concentrations up to 10 μM. PPTN blocks UDP-glucose inhibition of forskolin-induced cAMP accumulationand neutrophil chemotaxis towards UDP-glucose gradients with nM potency. | [References]
[1] Barrett MO, et al. A selective high-affinity antagonist of the P2Y14 receptor inhibits UDP-glucose-stimulated chemotaxis of human neutrophils. Mol Pharmacol. 2013 Jul;84(1):41-9. DOI:10.1124/mol.113.085654
[2] Lin J, et al. The P2Y14 receptor in the trigeminal ganglion contributes to the maintenance of inflammatory pain. Neurochem Int. 2019 Dec;131:104567. DOI:10.1016/j.neuint.2019.104567 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|